-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Changchun Hi-Tech (000661.SZ) issued an announcement. Recently, the company's subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as “Jinsai Pharmaceutical”), received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and Jinsai Pharmaceutical's application for registering 144 domestically produced drugs was approved. GenSci 144 tablets are an oral small molecule inhibitor targeting the neutral amino acid transporter SLC6a19 independently developed by Jinsai Pharmaceutical. It is registered as a Class 1 chemical and is intended for the treatment of chronic kidney disease (CKD).

Zhitongcaijing·07/30/2026 09:33:10
Listen to the news
Zhitong Finance App News, Changchun Hi-Tech (000661.SZ) issued an announcement. Recently, the company's subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as “Jinsai Pharmaceutical”), received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and Jinsai Pharmaceutical's application for registering 144 domestically produced drugs was approved. GenSci 144 tablets are an oral small molecule inhibitor targeting the neutral amino acid transporter SLC6a19 independently developed by Jinsai Pharmaceutical. It is registered as a class 1 chemical and is intended for the treatment of chronic kidney disease (CKD).